Rigel Pharmaceuticals, Inc. (RIGL) Income Statement Analysis

See more : Scoobeez Global, Inc. (SCBZ) Income Statement Analysis – Financial Results

Complete financial analysis of Rigel Pharmaceuticals, Inc. (RIGL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Rigel Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Rigel Pharmaceuticals, Inc. (RIGL)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.rigel.com

About Rigel Pharmaceuticals, Inc.

Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999
Revenue	116.88M	120.24M	149.24M	108.62M	59.29M	44.51M	4.48M	20.38M	28.90M	8.25M	7.15M	2.25M	4.75M	125.00M	750.00K	0.00	12.60M	33.47M	16.53M	4.73M	11.06M	15.79M	15.30M	13.22M	8.98M
Cost of Revenue	7.11M	1.75M	1.08M	895.00K	906.00K	287.00K	46.27M	63.45M	62.83M	67.70M	75.33M	78.78M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-7.56M	-1.91M
Gross Profit	109.77M	118.49M	148.15M	107.73M	58.38M	44.22M	-41.79M	-43.06M	-33.93M	-59.45M	-68.18M	-76.53M	4.75M	125.00M	750.00K	0.00	12.60M	33.47M	16.53M	4.73M	11.06M	15.79M	15.30M	20.78M	10.89M
Gross Profit Ratio	93.92%	98.55%	99.27%	99.18%	98.47%	99.36%	-931.87%	-211.27%	-117.43%	-720.56%	-953.54%	-3,401.24%	100.00%	100.00%	100.00%	0.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	157.17%	121.22%
Research & Development	24.52M	60.27M	65.24M	60.10M	52.89M	46.90M	46.27M	63.45M	62.83M	67.70M	75.33M	78.78M	69.35M	64.39M	90.74M	109.67M	70.36M	56.97M	52.04M	48.52M	43.36M	43.35M	32.31M	32.03M	17.11M
General & Administrative	0.00	0.00	0.00	0.00	0.00	70.00M	37.83M	20.91M	17.81M	31.80M	19.61M	22.85M	21.77M	25.29M	20.90M	27.04M	21.76M	19.55M	12.41M	13.08M	8.52M	9.45M	7.95M	6.69M	0.00
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	105.74M	112.45M	91.89M	76.60M	74.59M	70.00M	37.83M	20.91M	17.81M	31.80M	19.61M	22.85M	21.77M	25.29M	20.90M	27.04M	21.76M	19.55M	12.41M	13.08M	8.52M	9.45M	7.95M	6.69M	3.95M
Other Expenses	0.00	1.32M	3.52M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	7.56M	1.91M
Operating Expenses	130.26M	172.72M	157.13M	136.70M	127.47M	116.91M	84.10M	84.35M	80.64M	99.50M	94.94M	101.63M	91.12M	89.68M	111.65M	136.71M	92.13M	76.52M	64.45M	61.60M	51.88M	52.80M	40.26M	46.28M	22.97M
Cost & Expenses	137.37M	174.47M	158.21M	137.59M	128.38M	117.19M	84.10M	84.35M	80.64M	99.50M	94.94M	101.63M	91.12M	89.68M	111.65M	136.71M	92.13M	76.52M	64.45M	61.60M	51.88M	52.80M	40.26M	38.72M	21.06M
Interest Income	2.27M	684.00K	47.00K	582.00K	2.53M	2.20M	892.00K	437.00K	222.00K	243.00K	442.00K	537.00K	420.00K	303.00K	600.00K	4.44M	5.48M	5.70M	2.94M	966.00K	374.00K	856.00K	1.96M	1.08M	0.00
Interest Expense	6.87M	3.71M	4.86M	1.35M	335.00K	0.00	0.00	0.00	0.00	0.00	16.00K	17.00K	25.00K	91.00K	203.00K	160.00K	221.00K	290.00K	276.00K	324.00K	575.00K	870.00K	802.00K	933.00K	0.00
Depreciation & Amortization	1.24M	998.00K	1.16M	706.00K	683.00K	594.00K	465.00K	941.00K	1.44M	2.36M	2.59M	2.43M	1.96M	1.32M	1.40M	1.43M	1.34M	1.42M	1.18M	2.37M	3.18M	5.82M	6.76M	7.56M	1.91M
EBITDA	-16.98M	-53.87M	-11.29M	-27.69M	-65.88M	-69.89M	-77.53M	-63.03M	-50.30M	-88.89M	-85.20M	-96.94M	-83.99M	39.30M	-110.03M	-130.85M	-79.53M	-43.05M	-47.92M	-54.49M	-37.65M	-31.19M	-18.20M	-17.95M	-10.17M
EBITDA Ratio	-14.53%	-44.53%	-5.98%	-26.14%	-112.26%	-163.30%	-1,791.88%	-285.97%	-179.27%	-1,107.24%	-1,185.40%	-4,416.76%	-1,768.27%	29.55%	-14,519.07%	0.00%	-620.50%	-124.37%	-282.84%	-1,150.73%	-339.04%	-197.57%	-118.93%	-135.78%	-113.25%
Operating Income	-20.49M	-54.23M	-8.98M	-28.97M	-69.09M	-72.68M	-79.62M	-69.74M	-51.74M	-91.25M	-89.47M	-99.38M	-86.37M	35.32M	-112.04M	-136.71M	-79.53M	-43.05M	-47.92M	-56.87M	-40.83M	-37.02M	-24.96M	-25.51M	-12.08M
Operating Income Ratio	-17.53%	-45.10%	-6.01%	-26.67%	-116.53%	-163.30%	-1,775.56%	-342.15%	-179.07%	-1,106.05%	-1,251.31%	-4,416.76%	-1,818.27%	28.25%	-14,938.27%	0.00%	-631.17%	-128.60%	-289.98%	-1,201.50%	-369.31%	-234.46%	-163.11%	-192.96%	-134.46%
Total Other Income/Expenses	-4.60M	-3.02M	-4.81M	-771.00K	2.20M	2.20M	1.62M	525.00K	279.00K	341.00K	442.00K	537.00K	395.00K	2.57M	397.00K	4.28M	5.26M	5.41M	2.67M	612.00K	-370.00K	-14.00K	1.16M	145.00K	0.00
Income Before Tax	-25.09M	-58.57M	-17.31M	-29.74M	-66.89M	-70.48M	-77.99M	-69.22M	-51.46M	-90.91M	-89.03M	-98.84M	-85.97M	37.89M	-111.64M	-132.44M	-74.27M	-37.64M	-45.26M	-56.26M	-41.20M	-37.03M	-23.81M	-25.36M	0.00
Income Before Tax Ratio	-21.47%	-48.71%	-11.60%	-27.38%	-112.83%	-158.35%	-1,739.34%	-339.58%	-178.11%	-1,101.92%	-1,245.13%	-4,392.89%	-1,809.96%	30.31%	-14,885.33%	0.00%	-589.46%	-112.44%	-273.85%	-1,188.57%	-372.65%	-234.55%	-155.56%	-191.86%	0.00%
Income Tax Expense	0.00	3.02M	605.00K	647.00K	-348.00K	2.20M	-2.09M	4.30M	-1.72M	-2.70M	0.00	-2.43M	420.00K	91.00K	-93.00K	-89.00K	0.00	0.00	0.00	-612.00K	370.00K	0.00	0.00	0.00	286.00K
Net Income	-25.09M	-61.60M	-17.91M	-30.39M	-66.55M	-70.48M	-77.99M	-69.22M	-51.46M	-90.91M	-89.03M	-98.84M	-85.97M	37.89M	-111.55M	-132.35M	-74.27M	-37.64M	-45.26M	-56.26M	-41.20M	-37.03M	-23.81M	-25.36M	-12.37M
Net Income Ratio	-21.47%	-51.23%	-12.00%	-27.98%	-112.24%	-158.35%	-1,739.34%	-339.58%	-178.11%	-1,101.92%	-1,245.13%	-4,392.89%	-1,809.96%	30.31%	-14,872.93%	0.00%	-589.46%	-112.44%	-273.85%	-1,188.57%	-372.65%	-234.55%	-155.56%	-191.86%	-137.64%
EPS	-1.44	-3.40	-1.05	-1.76	-4.00	-4.39	-6.17	-7.33	-5.82	-10.37	-10.20	-1.32	-1.36	0.73	-2.73	-3.67	-2.57	-1.51	-2.07	-3.12	-3.62	-66.73	-5.75	-31.43	-355.49
EPS Diluted	-1.44	-3.40	-1.05	-1.76	-4.00	-4.39	-6.17	-7.33	-5.82	-10.37	-10.20	-1.32	-1.36	0.72	-2.73	-3.67	-2.57	-1.51	-2.07	-3.12	-3.62	-66.73	-5.75	-31.43	-355.49
Weighted Avg Shares Out	17.40M	17.24M	17.05M	16.88M	16.72M	16.05M	12.63M	9.44M	8.84M	8.77M	8.73M	74.88M	63.33M	52.06M	40.88M	36.03M	28.94M	24.94M	21.86M	18.05M	11.40M	554.94K	4.14M	806.92K	34.79K
Weighted Avg Shares Out (Dil)	17.40M	17.24M	17.05M	16.88M	16.74M	16.05M	12.63M	9.44M	8.84M	8.77M	8.73M	74.97M	63.33M	52.57M	40.88M	36.03M	28.94M	24.94M	21.86M	18.05M	11.40M	554.94K	4.14M	806.92K	34.79K

Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

April 10, 2024prnewswire.com

SOUTH SAN FRANCISCO, Calif. , April 10, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to Rigel's Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted...

Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma

April 4, 2024prnewswire.com

Olutasidenib induced durable composite complete remission in 43.8% of patients relapsed or refractory to prior venetoclax-based regimens Safety was consistent with the overall profile of olutasidenib Olutasidenib may offer a valuable treatment option for patients with mIDH1 previously treated with...

Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer

March 12, 2024prnewswire.com

SOUTH SAN FRANCISCO, Calif. , March 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the appointment of Lisa Rojkjaer, M.D.

Rigel Pharmaceuticals, Inc. (RIGL) Q4 2023 Earnings Call Transcript

March 5, 2024seekingalpha.com

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL ) Q4 2023 Earnings Conference Call March 5, 2024 4:30 AM ET Company Participants Ray Furey - Executive Vice President, General Counsel and Corporate Secretary Raul Rodriguez - President and Chief Executive Officer Dave Santos -...

Rigel Pharmaceuticals (RIGL) Reports Break-Even Earnings for Q4

March 5, 2024zacks.com

Rigel Pharmaceuticals (RIGL) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to earnings of $0.01 per share a year ago.

Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

March 5, 2024prnewswire.com

Fourth quarter 2023 Total Revenue of $35.8 million which includes TAVALISSE® net product sales of $25.7 million and REZLIDHIA ® net product sales of $3.9 million Expanded product portfolio with acquisition of U.S. rights to GAVRETO®, an FDA approved targeted...

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update

February 27, 2024prnewswire.com

SOUTH SAN FRANCISCO, Calif. , Feb. 27, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its fourth quarter and full year 2023 financial results after market close on Tuesday, March 5, 2024.

Rigel Pharmaceuticals: Upgrading To A 'Top Idea' Ahead Of Promising Q4/2023 Earnings Report

February 23, 2024seekingalpha.com

Rigel Pharmaceuticals reported promising preliminary Q4 and full-year 2023 results, with record-breaking net product sales for TAVALISSE and REZLIDHIA. The company's cash position remains healthy, providing support for its corporate, commercial, and pipeline initiatives. Investors should look out for updates...

Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®

February 22, 2024prnewswire.com

GAVRETO® (pralsetinib) is an FDA approved targeted therapy for the treatment of RET fusion-positive metastatic non-small cell lung cancer and advanced or metastatic thyroid cancer Acquisition of established U.S. marketed product further expands Rigel's portfolio and leverages Rigel's existing infrastructure...